Children's Hospital Los Angeles, citing recent U.S. Food and Drug Administration actions, on Monday said it has paused usage of Sarepta Therapeutics' gene therapy Elevidys in all patients with ...

U.S. stock indexes inched to more records to kick off a week full of profit updates from big U.S. companies. The S&P 500 rose ...

A nonprofit in Ohio is navigating uncertainty with several programs on the chopping block. Disability Rights Ohio serves as an advocate for people with disabilities.

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

As mothers of children with this disease, we have wept helplessly in recent months as friends — fellow members of a club we ...

Kostas Biliouris, BMO Capital Markets biotech analyst, joins CNBC's 'Squawk on the Street' to discuss the latest details on ...

A Cambridge-based company developing gene therapies for rare diseases is laying off more than a third of its workforce.

Sarepta Therapeutics refused a FDA request to halt shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy ...

British biopharmaceutical company GlaxoSmithKline will lay off 150 employees in its Cambridge operations by the end of March ...

Drugmaker Sarepta Therapeutics said late Friday it won't comply with a request from the Food and Drug Administration to halt ...

The FDA has placed multiple investigational gene therapy clinical trials on hold, signaling broader platform concerns.